DDInter1724 DDInter927
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Sulfamethoxazole {u} (Compound) resembles {v} (Compound) Sulfisoxazole
Sulfamethoxazole {u} (Compound) binds {v} (Gene) CYP2C8
Sulfamethoxazole {u} (Compound) upregulates {v} (Gene) SLC1A4
Sulfamethoxazole {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonamides
Sulfamethoxazole {u} (Compound) downregulates {v} (Gene) RPS4Y1
Sulfamethoxazole {u} (Compound) causes {v} (Side Effect) Purpura
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracaine
Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Sulfamethoxazole (Compound) binds CYP2C8 (Gene)
Sulfamethoxazole (Compound) upregulates SLC1A4 (Gene)
Sulfamethoxazole (Compound) is included by Sulfonamides (Pharmacologic Class)
Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene)
Sulfamethoxazole (Compound) causes Purpura (Side Effect)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine